The new guidance is also more certain about mycophenolate for renal disease, with a strong recommendation for use as an induction and maintenance agent, with azathioprine the other strong candidate for maintenance. EULAR also made a weak recommendation for mycophenolate with low-dose calcineurin inhibitors in severe nephrotic syndrome, in some circumstances.
For antiphospholipid antibody carriers, EULAR noted that a recent randomized, open-label trial comparing rivaroxaban against warfarin “was prematurely terminated due to an excess of thromboembolic events in the rivaroxaban arm. Thus, in patients with SLE-antiphospholipid syndrome, “use of novel oral anticoagulants for secondary prevention should be avoided.”
The group notes that management should aim at “remission of disease symptoms and signs, prevention of damage accrual, and minimization of drug side effects, as well as improvement of quality of life.” To that end, it said newly defined low disease-activity states, such as anscore of 3 or less on antimalarials, are useful to guide treatment, and have comparable rates of remission and flare prevention.
SOURCE: Fanouriakis A et al. Ann Rheum Dis. 2019 Mar 29.